Table 4.
Multivariate analyses of factors that might affect the presence of EGFR mutation
| Variable | Category | OR (95% CI) | P |
|---|---|---|---|
| Age | — | 0.99 (0.96–1.03) | 0.800 |
| Smoking | Former & current/never | 0.32 (0.18–0.55) | 0.000 |
| Gender | Female/male | 1.54 (0.91–2.60) | 0.110 |
| Tumor size | — | 1.05 (0.78–1.42) | 0.759 |
| TNM stage | I + II/III + IV | 1.52 (0.88–2.62) | 0.134 |
| Differentiation | Poor/moderate/well | 0.45 (0.26–0.77) | 0.004 |
| LNM (N1, N2) | Yes/no | 1.03 (0.64–1.69) | 0.892 |
| AIS | Yes/no | 1.33 (0.50–3.56) | 0.572 |
| MIA | Yes/no | 0.86 (0.25–3.04) | 0.818 |
| Lepidic predominant | Yes/no | 1.79 (0.83–3.88) | 0.140 |
| Acinar predominant | Yes/no | 2.03 (1.26–3.27) | 0.004 |
| Papillary predominant | Yes/no | 1.69 (0.91–3.13) | 0.096 |
| Micropapillary predominant | Yes/no | 0.95 (0.32–2.81) | 0.928 |
| Solid predominant | Yes/no | 0.51 (0.25–1.05) | 0.066 |
| IMA | Yes/no | 0.000 | 0.999 |
| Mucinous | Yes/no | 0.07 (0.01–0.60) | 0.015 |
AIS, adenocarcinoma in situ; CI, confidence interval; EGFR, epidermal growth factor receptor; IMA, invasive mucinous adenocarcinoma; LNM, lymph node metastasis; MIA, minimally invasive adenocarcinoma; OR, odds ratio; TNM, tumor node metastasis.